Leavitt Medical Associates of Florida d/b/a Ameriderm Research
Port Orange, Florida, 32127, United States
NCT Number: NCT03767153
Prospective, single centre, evaluator-blind study of the safety and performance of fractional radiofrequency (RF) for the treatment and reduction of acne scarring. The study will evaluate 50 treatment sites in subjects requesting treatment of their acne scarring. The study will involve three treatments on both sides of the face with 3-5 week intervals between each treatment. Subjects will be followed at 6 and 12 weeks after their last treatment. Analysis will be performed on all subjects who receive at least one treatment.
Looking for future studies?
Notify Me22 year and older
All sexes
Interventional
Not applicable
Port Orange, Florida, 32127, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Venus Viva™ fractional RF applicator has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.
Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.
Time frame: 12 Weeks Post-Final Treatment
Evaluate the efficacy of overall facial acne scar improvement assessed live by the Investigator and a subject assessment of facial appearance including the Global Aesthetic Improvement Scale (GAIS).
The Global Aesthetic Improvement Scale is a seven-grade subjective test.
Three independent evaluators evaluated before and after photographs and graded them for change.
Possible responses were (3) Very Much Improved, (2) Much Improved, (1) Improved, (0) No Change, (-1) Worse, (-2) Much Worse, and (-3) Very Much Worse. For reporting of outcomes, the higher the GAIS value, the greater the improvement (Range -3 to 3).
Time frame: 6 Weeks and 12 Weeks Post- Final Treatment
Subjects' assessment of satisfaction with the treatment using a 5 point Subject Satisfaction Scale at 6 Weeks and 12 weeks post-treatment.
The Subject Satisfaction Scale is a five-grade subjective test.
Participant were asked their satisfaction level post treatment.
Possible responses were (4) Very Satisfied, (3) Satisfied, (2) Having No Opinion, (1) Unsatisfied, and (0) Very Unsatisfied.
Time frame: 12 Weeks Post-Final Treatment
Subject's assessment of discomfort and pain after treatments as measured by a 10 cm visual analog scale (VAS).
The Visual Analog Scale is a scale from 0 cm (no pain) and 10 cm (pain as bad as it can be).
Possible responses were of 0 to 0.4 cm can be considered (no pain); 0.5 to 4.4 cm (mild pain), 4.5 to 7.4 cm (moderate pain), and 7.5 to 10 cm (severe pain).
Time frame: Up to 12 Weeks Post-Final Treatment
Subjects experiencing a treatment-related adverse event (AE) by 12 weeks post-treatment.
Time frame: 12 Weeks Post-Final Treatment
Subject's assessment of treatment tolerability as measured by a 5 point scale.
Participant were asked their tolerability level post treatment.
Possible scores were; (4) Very Tolerable, (3) Tolerable, (2) Having No Opinion, (1) Intolerable, and (0) Very Intolerable.
Venus Concept
Industry
Clinical Evaluation of the Safety and Performance of Fractional Radiofrequency for the Treatment and Reduction of Acne Scarring
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01696513
Acne Scars
Chicago, Illinois, United States
View Trial DetailsNCT02216864
Acne Scars
Chicago, Illinois, United States
View Trial DetailsNCT06338046
Acne Scars, Sebum Production
Naples, Italy
View Trial DetailsNCT07076784
Acne, Acne Scars
Seoul, South Korea
View Trial Details